share_log

bluebird bio | 8-K: Current report

bluebird bio | 8-K: Current report

bluebird bio | 8-K:重大事件
美股sec公告 ·  05/03 07:06
Moomoo AI 已提取核心信息
On April 30, 2024, bluebird bio, Inc. amended its Loan and Security Agreement (LSA) with Hercules Capital, Inc. and other lenders. This amendment is in response to the company's delay in filing its Annual Report on Form 10-K for 2023 and its Quarterly Report for Q1 2024 due to the restatement of its financials for 2022 and the first three quarters of 2023. The amendment includes revised financial reporting metrics and extended deadlines for the company to provide its financial statements for the year ended December 31, 2023, and for the quarter ended March 31, 2024. The company has stated that the late filings will not be considered a violation of its legal compliance obligations, provided the documents are filed by the new deadlines. The announcement also contains forward-looking statements regarding the company's expectations for filing the delayed reports and its performance under the LSA.
On April 30, 2024, bluebird bio, Inc. amended its Loan and Security Agreement (LSA) with Hercules Capital, Inc. and other lenders. This amendment is in response to the company's delay in filing its Annual Report on Form 10-K for 2023 and its Quarterly Report for Q1 2024 due to the restatement of its financials for 2022 and the first three quarters of 2023. The amendment includes revised financial reporting metrics and extended deadlines for the company to provide its financial statements for the year ended December 31, 2023, and for the quarter ended March 31, 2024. The company has stated that the late filings will not be considered a violation of its legal compliance obligations, provided the documents are filed by the new deadlines. The announcement also contains forward-looking statements regarding the company's expectations for filing the delayed reports and its performance under the LSA.
2024年4月30日,蓝鸟生物公司修订了与赫拉克勒斯资本公司和其他贷款机构签订的贷款和担保协议(LSA)。该修正案是对该公司因重报2022年和2023年前三个季度的财务状况而推迟提交其2023年10-K表年度报告和2024年第一季度季度报告的回应。该修正案包括修订后的财务报告指标,并延长了公司提供截至2023年12月31日的年度和截至2024年3月31日的季度财务报表的最后期限。该公司表示,延迟提交的文件不会被视为违反其法律合规义务,前提是文件是在新的截止日期之前提交的。该公告还包含有关公司对提交延迟报告的预期及其在LSA下的业绩的前瞻性陈述。
2024年4月30日,蓝鸟生物公司修订了与赫拉克勒斯资本公司和其他贷款机构签订的贷款和担保协议(LSA)。该修正案是对该公司因重报2022年和2023年前三个季度的财务状况而推迟提交其2023年10-K表年度报告和2024年第一季度季度报告的回应。该修正案包括修订后的财务报告指标,并延长了公司提供截至2023年12月31日的年度和截至2024年3月31日的季度财务报表的最后期限。该公司表示,延迟提交的文件不会被视为违反其法律合规义务,前提是文件是在新的截止日期之前提交的。该公告还包含有关公司对提交延迟报告的预期及其在LSA下的业绩的前瞻性陈述。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息